Bryn Mawr Trust Advisors LLC Has $5.47 Million Stake in Astrazeneca Plc $AZN

Bryn Mawr Trust Advisors LLC trimmed its stake in Astrazeneca Plc (NYSE:AZN) by 49.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,758 shares of the company’s stock after selling 27,644 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Astrazeneca were worth $5,474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Triumph Capital Management purchased a new position in Astrazeneca during the third quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new stake in Astrazeneca in the 4th quarter worth approximately $26,000. Mascoma Wealth Management LLC purchased a new stake in Astrazeneca in the 1st quarter worth approximately $26,000. Bangor Savings Bank lifted its position in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares in the last quarter. Finally, Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca during the 4th quarter valued at $30,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca struck an exclusive global license deal for the lung-cancer drug Zegfrovy, a move that could strengthen its oncology pipeline and long-term growth prospects. Article Title
• Positive Sentiment: UBS reiterated a Buy rating ahead of second-quarter results, saying AstraZeneca should deliver solid earnings and revenue. Article Title
• Neutral Sentiment: Analysts from both the U.S. and U.K. cited a mixed setup, with some optimism on near-term results but limited scope for AstraZeneca to raise full-year guidance. Article Title
• Negative Sentiment: HSBC downgraded AstraZeneca to Hold and cut its price target after the Wainua Phase 3 failure, saying the setback weakens the stock’s bull case. Article Title

Analysts Set New Price Targets

Several equities analysts have recently commented on AZN shares. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Stock Performance

Shares of AZN opened at $169.79 on Tuesday. The company’s fifty day moving average is $183.38 and its 200-day moving average is $188.67. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The firm has a market cap of $263.32 billion, a price-to-earnings ratio of 25.49, a price-to-earnings-growth ratio of 1.39 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Equities analysts expect that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.